Further Information
CYP19A1, cytochrome P450, family 19, subfamily A, polypeptide 1 , ARO, ARO1, CPV1, CYAR, CYP19, MGC104309, P-450AROM, aromataseN: cytochrome P450, family 19, cytochrome P450, subfamily XIX (aromatization of androgens), estrogen synthetase, flavoprotein-linked monooxygenase, microsomal monooxygenase
Peptide ELISA: antibody detection limit dilution 1:128000.Western Blot:Approx 50-55kDa band observed in Human Placenta lysates (calculated MW of 57.9kDa according to NP_000094.2 and NP_112503.1). Recommended concentration: 0.1-0.3ug/ml. Primary incubation was 1 hour.Immunohistochemistry:Paraffin embedded Human Placenta. Recommended concentration: 4ug/ml.
- Van Poznak CH, Hayes DF. Aromatase inhibitors for the treatment of breast cancer: is tamoxifen of historical interest only J Natl Cancer Inst. 2006 Sep 20;98(18):1261-3. No abstract available.
Supplied at 0.5 mg/ml in Tris saline, 0.02% sodium azide, pH7.3 with 0.5% bovine serum albumin.
Aliquot and store at -20?C. Minimize freezing and thawing.
500 ug/mL
Unconjugated
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
The immunogen for this antibody is: C-HDLSLHPDETKN
1588
cytochrome P450, family 19, subfamily A, polypeptide 1
CYP19A1
Homo sapiens
Liquid
NP_000094.2, NP_112503.1
13904858
Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide.
Cancer
This antibody is expected to recognise both reported isoforms (NP_000094.2 and NP_112503.1), which are identical
P11511